+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system--Mirena



Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system--Mirena



Collegium Antropologicum 32(4): 1059-1068



The advantages ensuing from the high contraceptive efficacy, positive effect on the parameters of the menstrual cycle as well as other values of the levonorgestrel-releasing intrauterine system may play an important role in women's sexual life. The aim of the study was to evaluate the effect of the levonorgestrel-releasing intrauterine system on the quality of life and sexual functioning of women. The research encompassed 200 women aged between 30 and 45. 52 women using the levonorgestrel-releasing intrauterine system were qualified to the study as the research group (Mirena Group). The control groups consisted of 48 women using a different type of intrauterine device (Control Group I--Other IUD) and 50 women using no contraception (Control Group II). A specific questionnaire with a general part concerning socio-demographic conditions, a part dealing with contraception and Polish version of self-evaluation inventories: Short Form-36 Health Survey, Female Sexual Function Index and Mell-Krat Scale was used as a research tool. Quality of life parameters for women using the Mirena system were higher than for the control groups, especially in the aspect of general health, energy/fatigue and emotional well-being. A significant beneficial effect of the levonorgestrel-releasing intrauterine system on sexual functioning (sexual desire and arousal) was also revealed in the study. Sexual dysfunctions were diagnosed in 20.8% of Other IUD, 34.7% of Control Group II and 9.6% of Mirena Group. Levonorgestrel-releasing intrauterine system increases female quality of life and sexual functioning parameters.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 053079101

Download citation: RISBibTeXText

PMID: 19149209


Related references

Levonorgestrel hormone releasing intrauterine system (Mirena) as a contraceptive in egg donors: case report. Journal of Assisted Reproduction and Genetics 22(3): 137-140, 2005

Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 67(2): 87-91, 2003

Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. European Journal of Contraception and Reproductive Health Care 23(1): 24-31, 2018

The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. Yearbook of Obstetrics Gynecology and Women's Health 2008: 236-237, 2008

The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial. Bjog 114(5): 563-568, 2007

Sexual functioning in women using levonorgestrel-releasing intrauterine systems as compared to copper intrauterine devices. Journal of Sexual Medicine 9(4): 1065-1073, 2012

Levonorgestrel-releasing intrauterine system Mirena® (Bayer) for the prevention and treatment of endometrial adenocarcinoma and the incidence of other malignancies in women. Ginekologia Polska 86(4): 305-310, 2015

In women over 35 years of age who smoke, does mirena (levonorgestrel-releasing intrauterine system) reduce the risk of DVTs compared to oral contraceptives?. Journal of the Oklahoma State Medical Association 106(9): 362-363, 2014

The effect of the levonorgestrel-releasing intrauterine system, Mirena® on mast cell numbers in women with endometriosis undergoing symptomatic treatment. European Journal of Obstetrics Gynecology and Reproductive Biology 159(2): 439-442, 2011

The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction. European Journal of Contraception and Reproductive Health Care 13(3): 231-237, 2008

Expulsion rate among users of two models of intrauterine devices (IUD), the Multiload 375 and the levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena). European Journal of Obstetrics Gynecology and Reproductive Biology 143(1): 64; Author Reply 64, 2009

Levonorgestrel releasing intrauterine system (Mirena) versus endometrial ablation (Novasure) in women with heavy menstrual bleeding: a multicentre randomised controlled trial. Bmc Women's Health 13: 32, 2013

A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertility and Sterility 97(3): 616, 2012

A randomized, phase Ii study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Yearbook of Obstetrics, Gynecology and Women's Health 2012: 265-266, 2012

Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 112(3): 171-178, 2011